NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

綠色化膿性傳染病治療全球市場:2020-2027

Global Pseudomonas Aeruginosa Infection Treatment Market - 2020-2027

出版商 DataM Intelligence 商品編碼 961511
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
綠色化膿性傳染病治療全球市場:2020-2027 Global Pseudomonas Aeruginosa Infection Treatment Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介
化膿性感染的治療市場的增長是由於院內感染的發生率增加,主要與膿瀉有關,抗菌藥物耐藥性激增,用於化膿性疾病的藥物的研究和開發也有所增加。與膿尿相關的醫院內感染(例如尿路感染(UTI),肺炎,囊性纖維化和血流感染)的患病率增加,將在預計的期間內治療化膿性感染預計將推動市場增長。另外,由於越來越多的抗生素用於化膿性感染的治療,出現了抗生素抗性菌株。

增加的投資和廣泛的研究與開發正在推動新療法的發展。領先的公司正在大力投資非抗生素治療方案的研發。一些製藥公司正在測試與抗生素具有化學相似性的新化合物。研發資金的增加有望促進市場增長。另一方面,長期使用抗生素會對患者產生不利影響並阻礙市場增長。

該報告調查了全球化膿性感染治療市場,並提供了系統的信息,例如市場概況,按細分市場和地區劃分的市場規模預測,主要公司的概況以及競爭情況分析。

目錄

第1章全球化膿性傳染病治療市場:調查方法/範圍

  • 調查方法
  • 調查目的/範圍

第2章全球化膿性傳染病治療市場:市場定義/概述

第3章全球化膿性傳染病治療市場:執行摘要

  • 市場細分:按治療
  • 市場細分:按藥品類別
  • 市場細分:按管理途徑
  • 市場細分:按分銷渠道
  • 市場細分:按地區

第4章全球化膿性傳染病治療市場:市場動態

  • 市場影響因素
    • 促進因素
    • 抑制因素
  • 市場機會
  • 影響分析

第5章全球化膿性傳染病治療市場:行業分析

  • 波特的五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 價格分析
  • 監管分析
  • 未滿足的需求
  • COVID19的影響分析

第6章全球化膿性傳染病治療市場:按治療方法

  • 簡介
  • 市場規模分析/同比增長率分析:按治療細分
  • 市場吸引力指數:按治療細分
    • 單藥治療
    • 聯合療法

第7章全球化膿性傳染病治療市場:按藥物類別

  • 簡介
  • 市場規模分析/同比增長率分析:按藥品類別
  • 市場吸引力指數:按藥品類別
    • Aminoglycoside
    • Monobactam
    • Carbapenem
    • Cephalosporin
    • 其他

第8章全球化膿性傳染病治療市場:按管理途徑

  • 簡介
  • 市場規模分析/同比增長率分析:按管理途徑劃分
  • 市場吸引力指數:按管理途徑劃分
    • 口頭
    • 靜脈

第9章全球化膿性傳染病治療市場:通過分銷渠道

  • 簡介
  • 市場規模分析/同比增長率分析:按分銷渠道細分
  • 市場吸引力指數:按分銷渠道細分
    • 醫院藥房
    • 零售藥房
    • 在線藥房
    • 其他

第10章全球化膿性傳染病治療市場:按地區

  • 簡介
    • 市場規模分析/同比增長率分析:按地區
    • 市場吸引力指數:按地區
  • 北美
    • 簡介
    • 特定地區的主要動態
    • 市場規模分析/同比增長率分析:按處理
    • 市場規模分析/同比增長率分析:按藥品類別
    • 市場規模分析/同比增長率分析:按管理途徑劃分
    • 市場規模分析/同比增長率分析:按分銷渠道
    • 市場規模分析/同比增長率分析:按國家
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第11章全球化膿性傳染病治療市場:競爭狀況

  • 競爭情景
  • 市場定位/份額分析
  • 併購分析

第12章公司簡介

  • Teva Pharmaceutical Industries Ltd.
    • 公司簡介
    • 投資組合/說明
    • 主要亮點
    • 財務概覽
  • AbbVie Inc. (Allergan plc)
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Co.
  • Lupin Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Gilead Sciences Inc.
  • Novartis AG

第13章全球化膿性傳染病治療市場:重要考慮因素

第14章全球化膿性傳染病治療市場:DataM

  • 附錄
  • 關於我們的公司和服務
  • 聯繫我們
目錄

Market Overview

The global pseudomonas aeruginosa infection treatment market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Pseudomonas Aeruginosa (also known as P. aeruginosa) is an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. Pseudomonas aeruginosa is a multidrug-resistant pathogen known for its intrinsically advanced antibiotic resistance mechanisms, its antibiotic resistance mechanisms, and association with serious illnesses including hospital-acquired infections (HAIs) such as ventilator-associated pneumonia and various sepsis syndromes. These bacteria frequently cause urinary tract infections (UTIs), lung infection, pneumonia, and chronic pain. People with low immune system are highly prone to affected by this infection.

The incidence of Hospital Acquired Infections (HAIs) has increased in recent years. As P. aeruginosa infection is one of the common infections in a hospital facility, the chances of being diagnosed with P. aeruginosa infection is high. This has led to an increase in research and development to find the treatment for P. aeruginosa. Several drugs are in the pipeline phases for the treatment of this infection.

Market Dynamics

The pseudomonas aeruginosa infection treatment market growth is majorly driven by the rising incidences of nosocomial infections associated with P. aeruginosa, rapidly growing antibacterial resistance, and increasing research & development of pseudomonas aeruginosa infection treatments.

The rise in the prevalence of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others, are expected to drive the growth of the global pseudomonas aeruginosa infection treatment market over the forecast period. There is a rise in the incidence of pseudomonas aeruginosa infections in intensive care which is projected to boosts the demand for newer pseudomonas aeruginosa infection treatment drugs. As per the Centers for Disease Control and Prevention (CDC), about 51,000 healthcare-associated pseudomonas aeruginosa infections occur in the United States annually. Over 6,000 (13%) of these are multidrug-resistant, with around 400 deaths per year attributed to these infections. The growing mortality rate owing to hospital-acquired infection(HAIs) is caused due to P. aeruginosa bacteria, especially in immunocompromised hosts. About 35 % of healthcare-acquired infections cause respiratory system infections, urinary infections, gastrointestinal infections, and other disorders, which leads to a rise in the demand for pseudomonas aeruginosa treatment.

In addition, increasing usage of antibiotics for the treatment of pseudomonas aeruginosa infection is also driving the market growth. Owing to the increasing use of antibiotics for the treatment of P. aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.

The rising investments and extensive research & development are boosting the development of novel therapies. The major players are investing heavily in R&D for non-antibiotic treatment options. Several pharma companies are testing novel compounds that bear chemical similarity with antibiotics. Increasing funding for research and development are expected to boost the market growth. For instance, in March 2019, Procarta Biosystems, a pharma company, received funding of USD 2 million from the Novo Holdings Repair Impact Fund to develop new therapies. These funds are used for developing novel therapies for the treatment of complicated urinary tract infections (UTIs) associated with pseudomonas aeruginosa infection. Also, in January 2019, CARB-X made an investment for a novel antibiotic for the treatment of serious lung infections caused by a slew of gram-negative bacteria, including pseudomonas aeruginosa.

However, extended use of antibiotics leads to harmful effects on the patient, which is likely to hamper the market growth. However, as P. aeruginosa shows the ability of drug resistance, several drug developers, who have limited funds are dissuaded from the market.

Segment Analysis

The pseudomonas aeruginosa infection treatment market is classified by medication into monotherapy and combination therapy. Among these, the combination therapy segment accounted for the largest market share in the global pseudomonas aeruginosa infection treatment market in 2019. Combination therapy is used for the patient who has developed resistance property against monotherapy. During this therapy, the combination of different drugs is used to treat bacterial infection. Rise in drug resistance in monotherapy has increased the demand for combination therapy for the treatment of pseudomonas aeruginosa infection. According to a research in 2018, published by Nicole Fosse et al., in PLoS One Journal, combination therapy was administered in 42.8%, and remaining 57.2% were treated with monotherapy. As per the research, combination therapy showed promising results and the mortality was lower in patients receiving combination therapy, compared to monotherapy. Also, the growth of combination therapy for the treatment of P. aeruginosa infection is due to its rapid onset of action, high bioavailability rate, cost-saving, and high efficiency. Hence, these factors are expected to boost the growth of the combination therapy segment.

Based on drug class, the global pseudomonas aeruginosa infection treatment market is segmented into cephalosporin, aminoglycoside, carbapenem, monobactam, and others Among these, the cephalosporin segment held the largest market share in 2019, owing to the increasing development of a new class of cephalosporin for the treatment of various P. aeruginosa infections by significant companies. A new cephalosporin (fifth-generation) was developed for the treatment of gram-negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. The launch of a new cephalosporin class of drugs is likely to boost the growth of the segment.

Based on the route of administration, the global pseudomonas aeruginosa infection treatment market has been segmented into oral, nasal, and intravenous. The intravenous segment is expected to dominate the global pseudomonas aeruginosa infection treatment market during the forecast period because most of the drugs available for the intravenous route as it gives rapid onset of action and high accuracy in dosing compared with other routes. Most of the physicians prefer the intravenous route for the administration of drugs, as in intravenous route, the entire dose reaches the systemic circulation immediately with rapid onset of action against bacteria.

Geographical Analysis

North America region is dominating the global pseudomonas aeruginosa infection treatment market accounted for the largest market share in 2019, owing to rising incidences of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others. As per the Agency for Healthcare Research and Quality report, 2019, around 1 of every 25 hospitalized patients in the United States are affected with hospital-acquired infection (HAI). This ratio translated to nearly 650,000 patients contract one of these infections annually. As per the American Association for the Advancement of Science, the proportion of patients with a hospital-acquired infection was 7.9% in 2017, in Canadian Hospitals. As pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries. The U.S. and Canada have a well-developed health care system which encourages research and development for the treatment of these infections. These countries have a major presence of diverse global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Europe is the second-largest market for pseudomonas aeruginosa infection treatment in terms of market value, due to rising incidences of pseudomonas aeruginosa infection, presence of major players and the early adoption of new products. For instance, in Germany, about 22,000 to 33,000 people are suffering from pseudomonas aeruginosa infection.

The Asia-Pacific pseudomonas aeruginosa infection treatment market expected to grow at the fastest growth rate over the forecast period. Developing countries such as China, India, and South Korea are expected to be lucrative markets for over the forecast period, owing to growing awareness, increasing incidences of healthcare-associated pseudomonas aeruginosa infection, rapidly developing healthcare infrastructure and high demand for advanced therapeutics. About 165,000 to 180,000 people in Australia suffer from hospital-acquired infections, as per a study and of these, about 9,000 have pseudomonas aeruginosa infection.

Competitive Landscape

The global players are manufacturing majority of the pseudomonas aeruginosa infection treatment drugs and therapies. Some of the key players which are contributing to the growth of the market include AbbVie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Co., Lupin Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Gilead Sciences Inc., Novartis AG, among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the pseudomonas aeruginosa infection treatment market globally. For instance,

  • In November 2019, Shionogi received the U.S. FDA approval for FETROJA (cefiderocol) for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following: susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
  • In September 2019, Armata Pharmaceuticals, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients.
  • In June 2019, Catalent Inc. purchased Bristol-Myers Squibb's Italy-based manufacturing facility. This deal will enable Bristol-Myers Squibb to maintain a strategic presence in Italy via the ongoing development and commercialization of new medicines.
  • In March 2019, Allergan received the U.S. FDA approval for the AVYCAZ treatment of complicated intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in pediatric patients.
  • In June 2018, Lupin Limited launched generic Tobramycin Inhalation Solution USP in the U.S. for the treatment of cystic fibrosis patients with P. aeruginosa.

Why Purchase the Report?

  • Visualize the composition of the pseudomonas aeruginosa infection treatment market segmentation by treatment, drug class, route of administration, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in pseudomonas aeruginosa infection treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of pseudomonas aeruginosa infection treatment market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global pseudomonas aeruginosa infection treatment market report would provide an access to an approx. 69 market data table, 64 figures and 280 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Pseudomonas Aeruginosa Infection Treatment market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Pseudomonas Aeruginosa Infection Treatment market - Market Definition and Overview

3. Global Pseudomonas Aeruginosa Infection Treatment market - Executive Summary

  • 3.1. Market Snippet by Treatment
  • 3.2. Market snippet by Drug Class
  • 3.3. Market snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Global Pseudomonas Aeruginosa Infection Treatment market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Hospital Acquired Infections (HAIs)
      • 4.1.1.2. Growing Investment in Drug Discovery for Pseudomonas Aeruginosa
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Drug Resistance Ability of Pseudomonas Aeruginosa
      • 4.1.2.2. XX
  • 4.2. Opportunity
  • 4.3. Impact Analysis

5. Global Pseudomonas Aeruginosa Infection Treatment market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. COVID-19 Impact Analysis

6. Global Pseudomonas Aeruginosa Infection Treatment market - By Treatment

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Segment
  • 6.3. Market Attractiveness Index, By Treatment Segment
    • 6.3.1. Monotherapy*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Combination Therapy

7. Global Pseudomonas Aeruginosa Infection Treatment market - By Drug Class

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.3. Market Attractiveness Index, By Drug Class Segment
    • 7.3.1. Aminoglycoside*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Monobactam
    • 7.3.3. Carbapenem
    • 7.3.4. Cephalosporin
    • 7.3.5. Others

8. Global Pseudomonas Aeruginosa Infection Treatment market - By Route of Administration

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 8.3. Market Attractiveness Index, By Route of Administration Segment
    • 8.3.1. Nasal*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Oral
    • 8.3.3. Intravenous

9. Global Pseudomonas Aeruginosa Infection Treatment market - By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Hospital Pharmacies*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others

10. Global Pseudomonas Aeruginosa Infection Treatment market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Pseudomonas Aeruginosa Infection Treatment market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Pseudomonas Aeruginosa Infection Treatment market- Company Profiles

  • 12.1. Teva Pharmaceutical Industries Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AbbVie Inc. (Allergan plc)
  • 12.3. Pfizer, Inc.
  • 12.4. Merck & Co., Inc.
  • 12.5. AstraZeneca
  • 12.6. Bristol-Myers Squibb Co.
  • 12.7. Lupin Pharmaceuticals, Inc.
  • 12.8. Janssen Pharmaceuticals, Inc.
  • 12.9. Gilead Sciences Inc.
  • 12.10. Novartis AG

LIST NOT EXHAUSTIVE

13. Global Pseudomonas Aeruginosa Infection Treatment market - Premium Insights

14. Global Pseudomonas Aeruginosa Infection Treatment market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us